ABSTRACT
Background and Aims: To study the epidemiology and features of the course of stroke in Uzbekistan according to the register for three years, followed by improvement of the system of prevention of patient care. Method(s): The stroke registry method is the best method not only for detecting new and recurrent cases of stroke among permanent residents of a certain region, but also for determining the main epidemiological indicators such as morbidity, mortality, which makes it possible for health authorities to take into account when planning a health care network. Result(s): The stroke registry was conducted throughout the Republic from January 1, 2019 to December 31, 2021.In the first year of the study 63000 cases In the second and third 45479 and 59280 of stroke were registered respectively.The average annual incidence of stroke per 1000 population in 2019 was 1.88, and in 2020 and 2021 this figure was 1.34 and 1.65, respectively. Moreover, the incidence rate tended to decrease from 1.88 to 1.34 per 1000 population in 2019-2020.It should be emphasized that the average annual incidence of stroke in 2020 did not decrease due to a decrease in true incidence rates, but due to the emerging Covid-19 pandemic, in which a large number of patients who had stroke, fearing to contract a viral infection, received treatment at home, without official registration Conclusion(s): When studying the mortality rates from stroke in the Republic for the study period, it was found that the average annual mortality per 1000 population was 0.37, 0.36 and 0.34 in 2019, 2020 and 2021, respectively.
ABSTRACT
Introduction: COVID-19 is the current global coronavirus pandemic caused by the SARS-CoV-2 coronavirus. The first reports of the disease outbreaks appeared in China on December 31, 2019 and the first clinical manifestations occurred earlier on December 8, 2019. On January 30, 2020, the World Health Organization declared the outbreak as a public health emergency of international concern. On March 11 it was declared a pandemic. Common symptoms include fever, cough, fatigue, shortness of breath, and anosmia (loss of smell).Complications can cause acute respiratory distress syndrome (ARDS) and pneumonia. The incubation period is usually around five days, but can range from two to fourteen days. Aim of the research isto study of clinical and diagnostic criteria for neurological disorders and changes of laboratory parameters in patients with COVID-19. Material and methods: We examined 31 patients who had undergone COVID-19 and were hospitalized at the private clinic "Neuromed-Service" named after academician N.M. Madjidov. There were 19 males and 14 females. The age of the patients varied from 18 to 75 years (the mean age made up 41 years). Results: Patients with inflammatory diseases of the peripheral nervous system (neuropathy, facial nerve, trigeminal neuralgia), considering an increase of C-reactive protein were performed anti-inflammatory therapy with NSAIDs and steroids (Dexamethasone intramuscularly). In patients with convulsive syndrome EEG was monitored using the "Neuron - range 2" (Russia). Diffusechangesinthebioelectricalactivityofthecerebralcortexwererevealedinthestudiedpatients.Epiactivityinthefronto-parietalregionofthebrain (against the background of taking anticonvulsants)was also recorded. The dose of anticonvulsants was increased for these patients and decongestants were prescribed. An increase in fibrinogen was also noted in the blood of these patients. Conclusion: Thereby, in patients after suffering COVID-19, the blood tests showed an increase of fibrinogen by more than 2 times and an increase of C-reactive protein. All this testifies the fact that in these patients after treatment, at the alleged improvement of their condition, the blood continued the process of thrombosis strengthening and inflammation persisted in tissues and organs. In patients who prematurely stopped taking antiplatelet agents and anti-inflammatory drugs after illness, neurological and other complications were developed.